Lexeo Therapeutics (LXEO) Gains from Sales and Divestitures (2025 - 2026)

Lexeo Therapeutics' (LXEO) quarterly Gains from Sales and Divestitures came in at $170812.0 in Q1 2026, up 225.69% year-on-year from $52446.0 in Q1 2025, and up 68.37% quarter-over-quarter from $101448.0 in Q4 2025.

Lexeo Therapeutics (LXEO) Gains from Sales and Divestitures (2025 - 2026) Analysis & Trends

Lexeo Therapeutics has disclosed Gains from Sales and Divestitures across 2 years of filings, most recently posting $170812.0 for Q1 2026.

  • Gains from Sales and Divestitures for Q1 2026 came in at $170812.0, up 225.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $170812.0 (up 225.69% YoY), and the FY2025 annual result was $101448.0, changed N/A from the prior year.
  • Gains from Sales and Divestitures came in at $170812.0 for Q1 2026 at Lexeo Therapeutics, up from $101448.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $170812.0 in Q1 2026 to a low of $52446.0 in Q1 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn -
7 Psyence Biomedical 229.39 Bn 229.38 Bn -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn
9 Abivax 90.15 Bn 90.15 Bn -
10 Lexeo Therapeutics 358.83 Mn 165.79 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 170,812.00
Mar 31, 2026 170,812.00
Dec 31, 2025 101,448.00
Dec 31, 2025 101,448.00
Sep 30, 2025 87,009.00
Sep 30, 2025 87,009.00
Jun 30, 2025 66,543.00
Jun 30, 2025 66,543.00
Mar 31, 2025 52,446.00
Mar 31, 2025 52,446.00